<DOC>
	<DOCNO>NCT00002681</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Interleukin-2 may stimulate person 's white blood cell kill leukemia lymphoma cell . Combining two therapy may effective treatment leukemia lymphoma . PURPOSE : Phase I/II trial study effectiveness monoclonal antibody therapy plus interleukin-2 treating patient leukemia lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Plus Interleukin-2 Treating Patients With Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess safety tolerability multidose regimen humanize anti-Tac monoclonal antibody ( HAT ) interleukin-2 ( IL-2 ) patient leukemia lymphoma . - Describe pharmacokinetics/pharmacodynamics HAT IL-2 multidose schedule , include serum half-life free HAT , area curve , volume distribution . - Evaluate immunogenicity HAT . - Identify immunologic parameter correlate efficacy . - Evaluate preliminary efficacy HAT patient . - Monitor patient receive indium-111-labeled HAT circulating infuse antibody pharmacokinetics , tumor imaging , bioactivity ( bind ability ) . OUTLINE : Patients stratify accord disease ( Hodgkin 's lymphoma v acute myelogenous leukemia v chronic myelogenous leukemia ) . Patients receive humanize anti-TAC monoclonal antibody ( HAT ) IV 30 minute day 1 , IV 30 minute every 7 day interleukin-2 subcutaneously daily . Treatment continue 1 year absence disease progression , unacceptable toxicity , development neutralize antibody . Patients follow weekly 2 month . PROJECTED ACCRUAL : A total 25 patient Hodgkin 's lymphoma 14 AML CML accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one follow malignancy : Hodgkin 's lymphoma Acute myelogenous leukemia Chronic myelogenous leukemia Failed standard therapy chronic phase standard therapy At least 30 % malignant cell reactive antiTac determine immunofluorescence study All Hodgkin 's lymphoma patient eligible due 100 % Tacpositivity ReedSternberg cell Measurable disease No symptomatic CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : Greater 2 month Hematopoietic : Not specify Hepatic : Bilirubin great 3 time normal No significant hepatic disease Renal : Creatinine great 3 time normal No significant renal disease Cardiovascular : No significant cardiovascular disease Pulmonary : No significant pulmonary disease Other : No significant endocrine , rheumatologic , allergic disease No HIVI antibody No active disease due following : Cytomegalovirus Herpes simplex virus I/II Hepatitis B C Tuberculosis Negative pregnancy test require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine antiTac monoclonal antibody Chemotherapy : At least 4 week since chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy Surgery : Not specify Other : Concurrent treatment allow complication primary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
</DOC>